The case for & against
Bull & Bear analysis
Bullish
Organon & Co. (NYSE: OGN) is a global healthcare company primarily focused on women's health and biosimilars. The firm is navigating through challenges created by the loss of exclusivity for some key products while seeking to maintain a strong market presence through strategic expansions and innovations in their product line. Organon operates within the dynamic biopharmaceutical sector, and its robust focus on women’s health positions it as a crucial player in addressing unmet healthcare needs in this domain.
Bull says
- ↑Nexplanon revenue to top $1B in 2025, driven by five-year indication
- ↑Hedlima biosimilars sales grew 63% YTD, expanding niche market share
- ↑Free cash flow of $960M in FY25 underlines strong cash generation
- ↑$440M Jada divestiture allocated to debt reduction, boosting leverage metrics
- ↑OPEX efficiency measures target ~$200M savings to support EBITDA margins
- ↑Strong liquidity and moderate leverage factors underpin financial resilience
Bear says
- ↓FY25 revenue declined 3% to $6.2B after key product exclusivity loss
- ↓Adjusted gross margin slid to 60.1% amid pricing pressure and mix shifts
- ↓Negative growth factor and low institutional ownership signal investor skepticism
- ↓U.S. policy constraints threaten Nexplanon uptake and contraceptive sales
- ↓Weak balance sheet factors heighten financing and operational risks
- ↓Rising competition in biosimilars and women's health compresses pricing
Investment themes with OGN
High Dividend Yield↑ +0.32%
Companies paying above-average dividends
AVGO · JPM · XOM
Pharmaceuticals↓ -1.67%
Drug development driving global healthcare solutions
JNJ · LLY · RPRX
Earnings Call · Q4 2024 · Mgmt. Guidance
Updated 07-15-2026neutral
Transcript signals
Bull points
- For the full year 2024, revenue was $6.4 billion, representing a 3% growth rate at constant currency. This is the third consecutive year that Organon has delivered constant currency revenue growth.
- In 2024, Nexplanon grew double-digit both in the U.S. and in international markets. Outside the U.S., growth in the Lemera region was particularly strong, driven by increased demand, tender expansions, as well as strong performance in Brazil.
- We remain very optimistic about the future of Nexplanon, especially with the potential of a five-year indication to sustain long-term Nexplanon growth.
Bear points
- That is reflective of an approximate $200 million headwind from Adizet's loss of exclusivity in Europe, which we will look to offset with growth in products like Vitamma, Emgality, Fertility, and of course, Nexplanon.
- With RENFLEX as an Entrezon, at the mature point in their longer-than-projected life cycle, will likely see a decline in biosimilars in the mid-single-digit range in 2025.
- There was an approximate $15 million impact from VBP that was really contained to the first half of the year, and related to round eight that began in the third quarter of 2023, and included Remeron and Kosar Heisar.
Read full transcript analysis ›